Director, CAR T Channel Strategy & Operations

requirements, and regulatory readiness. Support government pricing activities through cross-functional coordination, process governance, and operational oversight. Lead distribution governance, service-level management, and operational performance reviews across external partners. Support launch planning, market expansion, and new product introductions through scalable channel infrastructure. Develop reporting, analytics, and performance metrics that provide visibility into channel effectiveness and operational health. Identify and mitigate operational, regulatory, and commercial risks across the distribution network.

Qualifications Bachelor’s degree required; advanced degree preferred. 10+ years of experience in biotechnology, pharmaceutical, specialty distribution, market access, commercial operations, or related functions. Experience developing and executing channel strategies for specialty pharmaceuticals, cell therapies, gene therapies, or other complex therapies. Strong understanding of gross-to-net (GTN) principles, channel economics, distribution agreements, and commercial contracting. Demonstrated ability to design channel solutions that optimize GTN performance while meeting customer, provider, and patient

requirements. The national salary range for this position is from $190,000 to $230,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for

bonus,

benefits, and participation in Company’s stock plan. Apply for this job Links Home Platform & Pipeline Patients Inside Kyverna Education & Events Investors Careers Contact About Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101), is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff person syndrome, multiple sclerosis, and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. FOLLOW US ON SOCIAL Privacy Policy (US) Privacy Policy (EU/UK) Designed by Elegant Themes | Powered by WordPress

A meeting lands on your calendar

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.